• Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Auteur:Oudard, S; Caty, A; Humblet, Yves; Beauduin, Marc; Suc, E; Piccart-Gebhart, Martine; Rolland, Frédéric; Fumoleau, Pierre; Bugat, Roland; Houyau, P; Monnier, A; Sun, X; Montcuquet, P; Breza, J; Novak, J; Gil, Thierry; Chopin, D
Informations sur la publication:Annals of oncology, 12, 6, page (847-852)
Statut de publication:Publié, 2001-06
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adenocarcinoma -- drug therapy
Adenocarcinoma -- pathology
Aged, 80 and over
Androgens -- metabolism
Antineoplastic Agents, Phytogenic -- administration & dosage
Antineoplastic Agents, Phytogenic -- therapeutic use
Antineoplastic Agents, Phytogenic -- toxicity
Disease-Free Survival
Drug Administration Schedule
Leukopenia -- chemically induced
Middle Aged
Neoplasm Metastasis
Neutropenia -- chemically induced
Pain Measurement
Prostate-Specific Antigen -- blood
Prostatic Neoplasms -- drug therapy
Prostatic Neoplasms -- pathology
Quality of Life
Vinblastine -- administration & dosage
Vinblastine -- adverse effects
Vinblastine -- analogs & derivatives
Vinblastine -- therapeutic use
Note générale:Clinical Trial
Clinical Trial, Phase II
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't